GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of EDIT
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Wednesday for Editas Medicine, Inc
(Updated on Apr 17, 2024)

Sell candidate since Mar 14, 2024 Loss -31.17% PDF

The Editas Medicine, Inc stock price fell by -4.10% on the last day (Wednesday, 17th Apr 2024) from $5.85 to $5.61. It has now fallen 6 days in a row. During the last trading day the stock fluctuated 5.36% from a day low at $5.60 to a day high of $5.90. The price has fallen in 8 of the last 10 days and is down by -18.22% for this period. Volume has increased on the last day by 609 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 2 million shares were bought and sold for approximately $10.69 million.

Given the current short-term trend, the stock is expected to fall -10.05% during the next 3 months and, with a 90% probability hold a price between $5.05 and $9.38 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

EDIT Signals & Forecast

Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Editas Medicine, Inc stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $6.28 and $7.82. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Wednesday, February 28, 2024, and so far it has fallen -49.32%. Further fall is indicated until a new bottom pivot has been found. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss for Editas Medicine, Inc stock

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.300 between high and low, or 5.36%. For the last week, the stock has had daily average volatility of 5.06%.

Editas Medicine, Inc is oversold on RSI14 (12). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (EDIT) For The Upcoming Trading Day Of Thursday 18th

For the upcoming trading day on Thursday, 18th we expect Editas Medicine, Inc to open at $5.70, and during the day (based on 14 day Average True Range), to move between $5.22 and $6.00, which gives a possible trading interval of +/-$0.392 (+/-6.99%) up or down from last closing price. If Editas Medicine, Inc takes out the full calculated possible swing range there will be an estimated 13.98% move between the lowest and the highest trading price during the day.

With no support below and resistance from accumulated volume @ $6.63, some $1.02 (18.18%) from the current price of $5.61, our system finds the risk reward not very attractive.

Is Editas Medicine, Inc stock A Buy?

Editas Medicine, Inc holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -5.829 Strong Sell Candidate Unchanged

Predicted Opening Price for Editas Medicine, Inc of Thursday, April 18, 2024

Fair opening price April 18, 2024 Current price
$5.70 ( 1.66%) $5.61

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for EDIT

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 6.00 7.01 %
R2 5.89 4.97 %
R1 5.82 3.71 %
Current price: 5.61
Support S1 5.59 -0.379 %
S2 5.52 -1.64 %
S3 5.40 -3.68 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 6.87 22.46 %
R2 6.72 19.79 %
R1 6.63 18.18 %
Current price 5.61
Support S1 0 .
S2 0 .
S3 0 .

FAQ

What is the symbol for Editas Medicine, Inc Stock and on which exchange is it traded?
The symbol for Editas Medicine, Inc is EDIT and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Editas Medicine, Inc Stock?
Editas Medicine, Inc holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Editas Medicine, Inc Stock?
Editas Medicine, Inc Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Editas Medicine, Inc Stock.

What's the current price of Editas Medicine, Inc Stock?
As of the end of day on the 2024-04-17, the price of an Editas Medicine, Inc (EDIT) share was $5.61.

What is the 52-week high and low for Editas Medicine, Inc Stock?
The 52-week high for Editas Medicine, Inc Stock is $11.90 and the 52-week low is $5.60.

What is the market capitalization of Editas Medicine, Inc Stock?
As of the 2024-04-17, the market capitalization of Editas Medicine, Inc is 458.975M.

When is the next earnings date for Editas Medicine, Inc?
The upcoming earnings date for Editas Medicine, Inc is May 03, 2024.
Click to get the best stock tips daily for free!

About Editas Medicine, Inc

Editas Medicine Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, whic... EDIT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT